ReviewNeuropsychiatric disease and treatment2021
Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies.
Review in Neuropsychiatric disease and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Application of machine learning approaches to predict seizure-onset zones in patients with drug-resistant epilepsy: a systematic review.Frontiers in neurology · 2025Pooled it
- Etiology-specific trajectories of longitudinal functional connectivity and network topology in posttraumatic and mesial temporal lobe epileptogenesis.Experimental neurology · 2026Article
- cGAS-mediated type I IFN signaling contributes to disease progression in drug-refractory epilepsy.Nature neuroscience · 2026Article
- Bridging the Gap: Harnessing Phytochemical-Loaded Nanocarriers for Enhanced Epilepsy Treatment.Molecular neurobiology · 2026Review
- Anti-Inflammatory and Antioxidant Strategies in Epilepsy: From Molecular Mechanisms to Threshold Management.International journal of molecular sciences · 2026Review
- Metabolomic Profiling of Plasma in Children with Drug-Resistant Epilepsy: The Effect of the Ketogenic Diet on Energy and Amino Acid Pathways.Nutrients · 2026Article
- A Study on Protocol-based Treatment Change in Drug-resistant Epilepsy Patients in a Tertiary Care Center in Eastern India.Annals of Indian Academy of Neurology · 2026Article
- Review
- Risk factors for drug-resistant epilepsy according to sex: a cohort study conducted in a middle-income country.Arquivos de neuro-psiquiatria · 2026Article
- Effectiveness of adjunctive low-dose clobazam in adults with focal drug-resistant epilepsy and incomplete response to cenobamate: A real-world study.Epilepsia open · 2026Article
- Insulin resistance and epilepsy: an emerging pathophysiological nexus.Metabolic brain disease · 2026Review
- Epilepsy Treatment Outcome and Associated Factors in Children and Adolescents in a Resource-limited Setting: A Retrospective Cohort Study.Clinical medicine insights. Pediatrics · 2026Article
- Clinical Predictors of Drug-Resistant Epilepsy in Adults: An Analytical Observational Study.Cureus · 2026Article
- cGAS-mediated IFN-I signaling contributes to disease progression in drug-refractory epilepsy.bioRxiv : the preprint server for biology · 2026Article
- Nationwide Study of Pediatric Drug-Resistant Epilepsy in Estonia: Lower Incidence and Insights into Etiology.Pediatric reports · 2026Article
- 50 Hz Cortical stimulation increases interictal epileptiform discharges at the seizure onset zone.Brain communications · 2026Article
- EStiMapp: A practical tool for mapping clinical symptoms evoked by electrical stimulation in intracranial EEG for epilepsy surgery.Clinical neurophysiology practice · 2026Article
- Clinical application ofFrontiers in neuroscience · 2026Article
- Noninvasive Seizure Onset Zone Localization Using Janashia-Lagvilava Algorithm-Based Spectral Factorization in Granger Causality.Brain sciences · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistant epilepsy (DRE) is defined as the persistence of seizures despite at least two syndrome-adapted antiseizure drugs (ASD) used at efficacious daily dose. Despite the increasing number of available ASD, about a third of patients with epilepsy still suffer from drug resistance. Several factors are associated with the risk of evolution to DRE in patients with newly diagnosed epilepsy, including epilepsy onset in the infancy, intellectual disability, symptomatic epilepsy and abnormal neurological exam. Pharmacological management often consists in ASD polytherapy. However, because quality of life is driven by several factors in patients with DRE, including the tolerability of the treatment, ASD management should try to optimize efficacy while anticipating the risks of drug-related adverse events. All patients with DRE should be evaluated at least once in a tertiary epilepsy center, especially to discuss eligibility for non-pharmacological therapies. This is of paramount importance in patients with drug resistant focal epilepsy in whom epilepsy surgery can result in long-term seizure freedom. Vagus nerve stimulation, deep brain stimulation or cortical stimulation can also improve seizure control. Lastly, considering the effect of DRE on psychologic status and social integration, comprehensive care adaptations are always needed in order to improve patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.